| Literature DB >> 35541903 |
Jie Zhang1, Lei Wang1, Qianqian Song2, Mingbing Xiao1, Jie Gao3, Xiaolei Cao3, Wenjie Zheng1.
Abstract
Environmental and exogenous/ endogenous factors, in a setting of individual genetic predisposition, contribute to the cancer development. Over the years, epidemical evidence increasingly highlights the correlations of multiple cancer incentives and genetic alterations with cancer incidence. Unraveling the pivotal carcinogenesis events prompted by particular risk factors remarkably advances early surveillance and oncogenesis intervening. Traditional cell-based models and animal-based models are unrealistic and unreliable for translational study, respectively ascribing to the limited tumor heterogeneity and species-related variation. Organoid emerged as a fidelity model that well preserves the properties of its origin. With inherent quality of holistic perspective, organoid is therefore ideally suited for delineating the carcinogenesis under risk exposure, in favor of understanding pathogen-host interactions and alleviating cancer initiation. In this review, we have summarized the organoid model-based evidence that identified or validated carcinogenic risks, mainly including diet, aging, microbial infection, and chemical exposure. In addition, we envisioned the exciting prospect of organoid model in screening promising treatment and/or prevention during tumorigenesis. As a robust 3D in vitro system, organoid has been widespread applied in basial and clinical cancer research, which may elucidate crucial mechanisms of oncogenesis and develop novel targeting strategies. © The author(s).Entities:
Keywords: Carcinogenesis; Organoid; Prospect outlook; Risk factors; Robust model
Mesh:
Year: 2022 PMID: 35541903 PMCID: PMC9066109 DOI: 10.7150/ijbs.70406
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 10.750
Organoid models for studying risk factors in oncogenesis.
| Risk factor | Cancer type | Organoid culture system | Parallel model | Reference | ||||
|---|---|---|---|---|---|---|---|---|
| Organoid derivation | Culture system | Risk exposure modeling | Phenotype alteration | Mechanism | ||||
| HFD |
| Mouse and human-derived normal ISCs | Matrigel | Supplement with fatty acid constituent (palmitic acid, oleic acid or a lipid mixture) | Enforced organoid-initiating capacity | Enforced PPAR-δ signaling | HFD-fed mouse model |
|
| Intestinal tumor tissues of Apc /Kras compound mutant mouse | Matrigel | Co-culture with adipocyte | Dedifferentiation and aggressiveness of colon cancer cells | CPT1A mediated FAO | - |
| ||
| Human normal colonic tissues | Matrigel | Supplement with IL-13 to mimic obesity associated inflammation | Morphological capacity changes in organoids | IL-13 mediated signaling pathway | Obesity Mouse model |
| ||
| Cholesterol consumption |
| Isolated intestinal crypts of Lpcat3-deficient mice | Matrigel | - | Increased size, number, and complexity of organoids | Dietary-responsive phospholipid-cholesterol axis | Apcmin Mouse model |
|
| Vitamin E |
| Benign, premalignant and malignant human prostate cells | Matrigel | Supplement with vitamin E | Enforced growth and survival of premalignant organoids | Activation of fatty acid oxidation | - |
|
| Red meat consumption |
| Isolated normal murine intestinal crypts | Matrigel | Supplement with hemin or ferric chloride | Reduced viability of the organoids | Enforced ROS generation and oxidative DNA damage mediated by Nrf2 signaling and HO-1 stimulation | Human colonic epithelial cells |
|
| Alcohol consumption |
| Colon crypts from human healthy biopsies tissue | Matrigel | Prolonged ethanol exposure | - | Induced chromatin accessibility and differential gene expression associated with malignancies | - |
|
| Aging |
| Proximal intestinal crypts of BrafV600E-activated mice | Matrigel | Prolonged culture in medium with all niche factors | Stem-like state and a differentiation defects of accentuated polypoid growth phenotype | Abnormal CGI DNA methylation, or CIMP mediated by WNT pathway activation | - |
|
| Environmental risks |
| Lung, liver and mammary tissue of normal mouse | Matrigel | EMS, AA, DEN or SB treatment | No obvious changes | - | Mouse model |
|
|
|
| Healthy human intestinal tissue | Matrigel | Microinjecting pks(+) | DNA damage induced by pks(+) | Genotoxic colibactin induced SBS and ID signatures | - |
|
| Distal gut Microbiome |
| Crypts isolated from the jejunum or ileum of mouse | Matrigel | Gut microbiota-derived gallic acid | Enforced proliferation capacity of p53R172H organoids | TCF4-chromatin interaction suppression and H3K4me3 modification at genomic WNT promoters | Mouse model |
|
|
|
| Mouse stomachs tissue | Matrigel | Microinjecting | CagA-dependent epithelial cell proliferation and mis-localization of occludin at the tight junction | CagA-dependent β-catenin nuclear translocation | Mouse model |
|
| hiPSC-derived from antral tissue | Matrigel | Microinjecting | CagA-dependent epithelial cell proliferation | Phosphorylation of c-Met receptor | - |
| ||
| WT and Smox-/- mice | Matrigel | Supplement with | Induced inflammation, DNA damage | Activation of β-catenin signaling mediated by SMOX | - |
| ||
| Human gastric epithelial stem cells from surgical samples of human gastric corpus | Matrigel | Microinjecting | Cell polarity loss | RTK/PI3K/AKT signaling pathway and partitioning-defective polarity mediated by CagA-ASPP2 interaction | - |
| ||
| Human gastric epithelial stem cells from surgical samples of human gastric corpus | Matrigel | Microinjecting | Gastric gland lineages mounted a strong inflammatory response in contrast to pit lineages | Activation of NF-κB pathway | - |
| ||
|
|
| Primary epithelial cells of human and murine gallbladder | Matrigel, ALI | Co-cultured with | Typhoid toxin dependence host cell DNA damage | Typhoid toxin induced DNA double-strand breaks and | - |
|
| HBV |
| hiPSCs | Matrigel | Supplement with HBV | Decreased ALB secretion, increased ALT and LDH levels, induced EMT phenotype | - | - |
|
| HPV |
| Human primary keratinocytes, co-cultured with fibroblast, LCs | Matrigel, ALI | Supplemented with HPV | Host immune evasion by HPV | - | - |
|
| Inflammation |
| IECs isolated from mouse colon | Matrigel | Supplement with a mixture of cytokines and bacterial components | - | Activation of NF-κB signaling pathway | - |
|
Abbreviation: HFD: high fat diet; CRC: colorectal cancer; ISCs: intestinal stem cells; CPT1A: carnitine palmitoyltransferase I; FAO: fatty acid oxidation; Lpcat3: lysophosphatidylcholine acyltransferase 3; PCa: prostatic cancer; ROS: reactive oxygen species; HO-1: heme oxygenase-1; COAD: colon adenocarcinoma; CGI: CpG-island; CIMP: CpG island methylator phenotype; EMS: ethyl methanesulfonate; AA: acrylamide; DEN: diethylnitrosamine; SB: sodium benzoate; : Escherichia coli; SBS: single base substitution; ID: small indel; TCF4: T cell factor 4; : Helicobacter pylori; GC: gastric cancer; CagA: cytotoxin-associated gene A; hiPSC: human induced pluripotent stem cells; SMOX: spermine oxidase; ASPP2: apoptosis-stimulating protein of p53 2; HBV: Hepatitis B Virus; HCC: hepatocellular carcinoma; EMT: tumor microenvironment; GBC: gallbladder cancer; ALI: air-liquid interface; HPV: human papillomavirus; LCs: Langerhans cells; IECs: intestinal epithelial cells.